Pre-made Atoltivimab benchmark antibody ( Whole mAb, anti-Zaire Ebolavirus GP therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-038

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-038 Category Tag

Product Details

Pre-Made Atoltivimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Atoltivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).

Products Name (INN Index)

Pre-Made Atoltivimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody

INN Name

Atoltivimab

Target

Zaire Ebolavirus GP

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2018

Companies

Regeneron Pharmaceuticals

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Ebola virus infections

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

Zaire Ebolavirus GP

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide